Stocks in Focus: Cypress Energy Partners, L.P. (NYSE:CELP), Pandora Media Inc (NYSE:P), Bacterin International Holdings, Inc. (NYSEMKT:BONE), Merck (NYSE:MRK), DHT Holdings (NYSE:DHT)

Cypress Energy Partners, L.P. (NYSE:CELP) belongs to Basic Materials sector. Its net profit margin is -4.90% and weekly performance is -2.45%. On last trading day company shares ended up $15.52. Cypress Energy Partners, L.P. (NYSE:CELP) distance from 50-day simple moving average (SMA50) is -3.03%. Cypress Energy Partners, L.P. (NYSE:CELP) is slated to report earnings for the current quarter on 13 August 2015.

On 10 July, Pandora Media Inc (NYSE:P) shares fell -0.40% and was closed at $15.05. P EPS growth in last 5 year was 0.00%. Pandora Media Inc (NYSE:P) year to date (YTD) performance is -15.59%. On 8 July, Pandora Media Inc (NYSE:P) has closed a deal to acquire music analytics provider Next Big Sound for an undisclosed sum. The deal puts the finishing touches on a plan to give the industry more data about artists and their fans.

On 10 July, Bacterin International Holdings, Inc. (NYSEMKT:BONE) shares remains unchanged and was closed at $3.05. BONE EPS growth in last 5 year was 0.00%. Bacterin International Holdings, Inc. (NYSEMKT:BONE) year to date (YTD) performance is 0.66%. Bacterin International Holdings, Inc. (NYSEMKT:BONE) today announced preliminary, unaudited revenue for the second quarter of 2015. The Company is expecting total revenue for the second quarter of 2015 to be in the range of $10.0 million to $10.2 million, representing an increase of 12–15% when compared to $8.8 million reported for the second quarter of 2014. This also represents a sequential increase of 5–7% when compared to $9.5 million for the first quarter of 2015.

Merck & Co. Inc. (NYSE:MRK) ended the last trading day at $57.95. Company weekly volatility is calculated as 1.48% and price to cash ratio as 10.49. Merck & Co. Inc. (NYSE:MRK) showed a weekly performance of 0.49%. On 8 July, Merck & Co. Inc. (NYSE:MRK) and Allergan plc (AGN) released that they have signed into an contract under which Allergan will purchase the exclusive worldwide rights to Merck’s investigational small molecule oral calcitonin gene-related peptide receptor antagonists, which are being developed for the treatment and prevention of migraine.

DHT Holdings, Inc. (NYSE:DHT) shares increased 2.96% in last trading session and ended the day at $8.01. DHT Gross Margin is 48.10% and its return on assets is 3.00%. DHT Holdings, Inc. (NYSE:DHT) quarterly performance is 2.93%. Zacks downgraded shares of DHT Holdings Inc. (NYSE:DHT) from a buy rating to a hold rating in a research note.

Leave a Reply

Your email address will not be published. Required fields are marked *